Market Place
Sourcing Support
Akamis Bio Enrolls 1st Patient in Phase 1b FORTRESS Trial of NG-350A
03 Apr 2025 //
BUSINESSWIRE
Akamis Bio Highlights Data Showing Potential of its Adenovirus Vector Technology
03 Oct 2023 //
BUSINESSWIRE
Akamis Bio Strengthens Leadership Team with Key Executive Appointments
06 Jul 2023 //
BUSINESSWIRE
Akamis Bio, Parker Institute, and CRI to assess pancreatic cancer therapies
17 Feb 2023 //
CLINICAL TRIALS ARENA
PsiOxus to Present Data on Potential of Its New T-SIGn Tumor-Selecting Vector
15 Sep 2021 //
BUSINESSWIRE
PsiOxus and bluebird bio Present Novel Data Combining PsiOxus T-SIGn
14 Apr 2021 //
BUSINESSWIRE
BMS, PsiOxus add an asset to Opdivo-oncolytic virus combo deal
07 Apr 2021 //
FIERCEBIOTECH
PsiOxus Updates Agreement with Bristol Myers Squibb
06 Apr 2021 //
BUSINESSWIRE
PsiOxus Therapeutics Updates Agreement with Bristol Myers
06 Apr 2021 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.